GlassScriptPhysician profile
Sara L Grater
NPI 1831573799
$23,487.61
in general payments reported to CMS, 2019-2025
71 companies · $5,045 in 2025
The $5,045 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,238 · 2022: $3,253 · 2023: $4,998 · 2024: $5,955 · 2025: $5,045.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $644 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,203.05 |
| Education | $644.21 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,589.41 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $1,479.43 | 2021-2025 | Ultomiris, Soliris |
| Biogen, INC. | $1,457.87 | 2021-2025 | Tysabri, Vumerity, Skyclarys |
| Jazz Pharmaceuticals INC. | $1,336.55 | 2021-2025 | |
| Sk Life Science, INC. | $1,084.28 | 2021-2025 | Xcopri |
| Ucb, INC. | $1,059.00 | 2021-2025 | Briviact, Nayzilam, Zilbrysq |
| Neurocrine Biosciences, INC. | $1,020.89 | 2021-2025 | Ingrezza, Ongentys |
| Teva Pharmaceuticals USA, INC. | $976.07 | 2021-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Harmony Biosciences LLC | $954.85 | 2022-2025 | Wakix |
| Emd Serono, INC. | $887.14 | 2021-2025 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $788.69 | 2021-2025 | |
| Genentech USA, INC. | $759.18 | 2021-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Axsome Therapeutics, INC. | $751.54 | 2022-2025 | Sunosi, Symbravo |
| Eisai INC. | $662.78 | 2022-2025 | |
| Acadia Pharmaceuticals INC | $633.48 | 2021-2025 | Nuplazid, Daybue |
Show all 71 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $608.52 | 2021-2025 | Vyepti, Rexulti |
| Lilly USA, LLC | $459.62 | 2021-2025 | Kisunla, Amyvid, Reyvow |
| Argenx US, INC. | $432.16 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Amgen INC. | $389.66 | 2021-2025 | Aimovig, Uplizna |
| Genzyme Corporation | $361.75 | 2021-2025 | |
| Inspire Medical Systems, INC. | $361.40 | 2022-2025 | Inspire |
| Pfizer INC. | $317.21 | 2023-2025 | |
| Tg Therapeutics, INC. | $291.19 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $275.11 | 2022-2025 | Hyqvia, Gammagard |
| Biohaven Pharmaceuticals, INC. | $248.84 | 2021 | |
| Celgene Corporation | $248.18 | 2021-2025 | Zeposia |
| Avion Pharmaceuticals | $228.27 | 2022-2023 | Dhivy |
| Grifols USA, LLC | $219.63 | 2021-2025 | Gamunex-C |
| Janssen Pharmaceuticals, INC | $206.43 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $206.11 | 2021-2024 | Acthar |
| Octapharma USA, INC. | $201.07 | 2024-2025 | Octagam Immune Globulin (Human), Panzyga |
| Impel Pharmaceuticals INC. | $198.16 | 2023 | Trudhesa |
| Vanda Pharmaceuticals INC. | $197.80 | 2024-2025 | Ponvory |
| Xeris Pharmaceuticals, INC. | $170.00 | 2021-2025 | Keveyis |
| Neurelis, INC. | $160.11 | 2021-2025 | Valtoco |
| Averitas Pharma INC. | $158.15 | 2023 | Qutenza |
| Biohaven Pharmaceutical Holding Company LTD. | $139.86 | 2022 | |
| Avanir Pharmaceuticals, INC. | $127.72 | 2021-2022 | |
| Avadel Cns Pharmaceuticals, LLC | $118.20 | 2023-2025 | Lumryz |
| Csl Behring | $115.62 | 2021-2025 | Hizentra |
| Sumitomo Pharma America, INC. | $110.11 | 2023 | Aptiom, Latuda |
| Horizon Therapeutics Plc | $106.70 | 2022-2023 | Uplizna |
| Sunovion Pharmaceuticals INC. | $93.64 | 2021-2022 | |
| Catalyst Pharmaceuticals, INC. | $92.10 | 2023-2024 | Fycompa |
| Idorsia Pharmaceuticals US INC | $90.09 | 2023-2025 | Quviviq, Quviviq |
| Otsuka America Pharmaceutical, INC. | $90.07 | 2023-2025 | Rexulti, Nuedexta |
| Ge Healthcare | $75.99 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $72.23 | 2021-2022 | |
| Kyowa Kirin, INC. | $67.12 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $65.70 | 2021 | |
| Azurity Pharmaceuticals, INC. | $65.22 | 2024-2025 | Horizant |
| Impel Pharmaceuticals LLC | $53.18 | 2024-2025 | Trudhesa |
| Tanabe Pharma America, INC. | $52.18 | 2021-2025 | Radicava |
| Amneal Pharmaceuticals LLC | $49.95 | 2023 | Rytary |
| Genentech, INC. | $49.95 | 2021 | |
| Sandoz INC. | $48.57 | 2024 | |
| Almatica Pharma LLC | $42.27 | 2021 | |
| Abbott Laboratories | $39.23 | 2021-2022 | |
| Acorda Therapeutics, INC | $39.06 | 2021 | |
| Nevro Corp. | $36.82 | 2023-2024 | Senza |
| Scilex Pharmaceuticals INC. | $36.71 | 2023-2024 | Ztlido |
| Kedrion Biopharma, INC. | $34.76 | 2024-2025 | Albuked, Rhogam Ultra-Filtered Plus, Kedrab |
| Adamas Pharmaceuticals, INC. | $31.69 | 2021 | |
| Merz Pharmaceuticals, LLC | $26.62 | 2025 | Xeomin, Inbrija |
| Insightec,INC | $23.90 | 2025 | Exablate |
| Grt US Holding, INC. | $22.51 | 2022 | |
| Janssen Biotech, INC. | $21.05 | 2025 | |
| Phathom Pharmaceuticals, INC. | $20.55 | 2025 | Voquezna |
| Cycle Pharmaceuticals INC | $19.10 | 2024 | Tascenso Odt |
| Banner Life Sciences, LLC | $15.78 | 2023 | |
| Nobelpharma America, LLC | $12.83 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Grater listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.